Ian L McAllister
Overview
Explore the profile of Ian L McAllister including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
2579
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Hunt A, Nguyen V, Creuzot-Garcher C, Alforja S, Gabrielle P, Zarranz-Ventura J, et al.
Br J Ophthalmol
. 2021 Mar;
106(8):1178-1184.
PMID: 33712484
Background/aims: To compare the efficacy of ranibizumab (0.5 mg) with aflibercept (2 mg) in the treatment of cystoid macular oedema due to branch retinal vein occlusion (BRVO) over 12 months....
22.
Bhikoo R, Chong S, McLeod K, Heyworth P, McAllister I
Ocul Immunol Inflamm
. 2020 Nov;
30(4):995-997.
PMID: 33216649
No abstract available.
23.
Charng J, Lamey T, Thompson J, McLaren T, Attia M, McAllister I, et al.
Transl Vis Sci Technol
. 2020 Sep;
9(10):9.
PMID: 32974081
Purpose: Microperimetry is commonly used to assess retinal function. We perform cross-sectional and longitudinal analysis on microperimetry parameters in retinopathy and explore end points suitable for future clinical trials. Methods:...
24.
Pearce I, Clemens A, Brent M, Lu L, Gallego-Pinazo R, Minnella A, et al.
PLoS One
. 2020 Jun;
15(6):e0234739.
PMID: 32555630
Objective: To evaluate the effectiveness, safety, and treatment patterns of ranibizumab 0.5 mg in treatment-naïve patients with branch retinal vein occlusion (BRVO) enrolled in the LUMINOUS™ study. Study Design: A...
25.
McAllister I
Asia Pac J Ophthalmol (Phila)
. 2020 Jun;
9(3):239-249.
PMID: 32501894
Treatments for central retinal vein occlusion (CRVO) have improved dramatically with the advent of intravitreal agents aimed at blocking the effects of the dominant hypoxia-induced upreglulated cytokine, which is vascular...
26.
Tang Y, Chang A, Campbell W, Connell P, Hunyor A, McAllister I, et al.
Retina
. 2020 Jan;
40(2):290-298.
PMID: 31972799
Purpose: To report the outcomes of eyes receiving surgical management for traumatic macular holes. To describe the preoperative and postoperative optical coherence tomography features of traumatic macular holes and to...
27.
Richards J, House P, McAllister I, A Rahman A
Clin Exp Ophthalmol
. 2019 Dec;
48(3):408-409.
PMID: 31872498
No abstract available.
28.
Gillies M, Hunyor A, Arnold J, Guymer R, Wolf S, Pecheur F, et al.
Ophthalmology
. 2019 Oct;
127(2):198-210.
PMID: 31619357
Purpose: To investigate differences in the development of macular atrophy (MA) over 24 months between treat-and-extend (T&E) ranibizumab and aflibercept in patients with neovascular age-related macular degeneration (nAMD). Design: A...
29.
Essex R, Hunyor A, Moreno-Betancur M, Yek J, Kingston Z, Campbell W, et al.
Ophthalmol Retina
. 2019 May;
2(11):1143-1151.
PMID: 31047553
Purpose: To present the visual and safety outcomes of surgery for primary idiopathic macular holes including predictors of visual acuity and the impact of combined phacovitrectomy surgery. Design: Registry-style, prospective,...
30.
Yek J, Hunyor A, Campbell W, McAllister I, Essex R
Ophthalmol Retina
. 2019 May;
2(8):757-764.
PMID: 31047526
Purpose: To describe the anatomic and visual outcomes of eyes undergoing reoperation after failed primary surgery for idiopathic macular hole. Design: Prospective registry study. Participants: One hundred three patients who...